- Home
- BJDX
as 12-18-2024 3:32pm EST
Bluejay Diagnostics Inc is a medical diagnostics company. It is developing rapid tests using whole blood using its Symphony technology platform to improve patient outcomes in critical care settings. The company's first product, the Symphony IL-6 test, is for the monitoring of disease progression in critical care settings and is a clinically established inflammatory biomarker for the assessment of the severity of infection and inflammation across many disease indications, including sepsis.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | ACTON |
| Market Cap: | 1.8M | IPO Year: | 2021 |
| Target Price: | N/A | AVG Volume (30 days): | 959.8K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -163.76 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.03 - $1272.00 | Next Earning Date: | 11-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Bluejay Diagnostics Inc. News
BJDX Breaking Stock News: Dive into BJDX Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
Bluejay Diagnostics Announces Reverse Stock Split
MT Newswires
6 months ago
Bluejay Diagnostics Closes $8.8 Million Public Offering
GlobeNewswire
6 months ago
Bluejay Diagnostics Announces Closing of $8.75 Million Underwritten Public Offering
MT Newswires
6 months ago
Top Midday Decliners
GlobeNewswire
6 months ago
Bluejay Diagnostics Announces Pricing of $8.75 Million Underwritten Public Offering
GlobeNewswire
6 months ago
SYMON-I Study of Symphony IL-6 Suggests Prediction of Mortality in Sepsis Patients
GlobeNewswire
6 months ago
Bluejay Diagnostics Announces Reverse Stock Split
CNW Group
6 months ago
Lotto 6/49 - $64 million up for grabs in the next draw!
Compare BJDX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BJDX Bluejay Diagnostics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.